Ceregene, the San Diego-based gene therapy company, said today it has raised $11.5 million in a Series D venture round. Hamilton BioVentures and Alta Partners led the deal, which included MPM Capital and Investor Growth Capital. Ceregene said plans to use the money to complete a Phase 2b clinical trial of its experimental treatment CERE-120 for Parkinson’s disease. Back in December 2008, Ceregene said a mid-stage trial of 58 patients failed to show a statistically significant advantage when compared to a placebo. For more on Ceregene and its strategy against Parkinson’s disease, check out this profile we ran back in October 2008.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
